NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
09. Dezember 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
20. November 2024 16:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
13. November 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations.
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
12. September 2024 16:05 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Biongevity Enhances Longevity Strategy with Harish Consul as Chief Venture Capital Advisor
04. September 2024 09:49 ET
|
BioAro
Biongevity appoints Harish Consul as Chief Venture Capital Advisor, accelerating global growth with innovative precision health and longevity strategies.
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
25. Juli 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy...
Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024
04. März 2024 10:00 ET
|
Baylor Genetics
Researchers present abstracts and poster sessions showcasing research and clinical solutions.
Joint session planned with Illumina.
Epigenetics Market Predicted to Garner USD 12.7 Billion By 2033, At CAGR 19.2% | Exclusive Report by Marketresearch.biz
16. Januar 2024 03:58 ET
|
MarketResearch.biz
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The epigenetics market was valued at USD 2.3 billion in 2023 with a significant growth and is projected to reach at USD 12.7 billion by 2033 with a CAGR...
Baylor Genetics Accelerates Growth, Combines Clinical and Scientific Expertise with Commercial Capabilities to Meet Increased Needs of Patients, Providers and Partners
03. Januar 2024 10:00 ET
|
Baylor Genetics
Company Expands Test Offerings, Lab Technology, and Customer-Centric Tools Rapid Comprehensive Whole Genome and Exome Sequencing, Disease-Specific Panels and Customizable Solutions Advance Diagnoses...
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
28. November 2023 07:42 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...